Lily Li

Lily Li is a Principal at Northpond Ventures where she focuses on investments in life science tools, diagnostics and precision medicine. Lily is a board director at 1859 Inc and Ansa Biotechnologies and holds board observer roles at ChromaCode, Delfi Diagnostics, Emulate, Encodia, Ultivue, and Vizgen.

She was a board director at Personal Genome Diagnostics (PGDx) which was acquired by LabCorp. Previously, Lily was an Associate Director of Corporate and Business Development at Illumina (NASDAQ: ILMN), where she structured and led strategic partnerships to support company growth across clinical markets.

Prior to Illumina, Lily led strategic marketing and business development at NanoString Technologies, Inc. (NASDAQ: NSTG). Lily was also a management consultant in the life sciences practice at L.E.K. Consulting, where she served as a strategic advisor to a broad range of corporate clients and life science investors. Lily received her Ph.D. in molecular and systems pharmacology from Emory University. She also holds a B.S. in biology from Tsinghua University.